Analytical reports routinely compress several questions into a single word: quality. A chromatographic percentage may be repeated as though it also names the principal peak and accounts for every impurity. In the opposite direction, agreement with an expected mass may be treated as a purity result. Both moves enlarge the measurement after the fact.
Purity and identity are related, but they are not interchangeable. Identity asks whether the evidence supports that the tested material contains the intended molecular species. A chromatographic purity result often reports the relative detector responses assigned to resolved components under a specified separation, detection, and calculation procedure. Analytical claims should inherit the boundaries of the method, conditions, detector, sample, and validation purpose that produced them. ICH Q2(R2) reinforces this discipline by treating identity, purity, and impurity testing as distinct analytical uses and tying procedure performance to intended purpose.1
A Percentage and a Name Are Not the Same Result
Chromatographic separations exploit differences in how sample components interact with stationary and mobile phases; whether particular components resolve depends on the procedure. Retention behavior is conditional: column chemistry, mobile-phase composition, flow, temperature, and isocratic or gradient elution all influence the result. The detector converts responsive species reaching it into signals whose magnitudes depend on detector type and conditions. A chromatogram is evidence about a particular separation-and-detection system, not an inventory independent of that system.3
Working in analytical science?
Register for a FREE Separation Science account to subscribe to the Separation Science Newsletter.
Molecular identity poses a different problem: does the evidence discriminate the intended species from plausible alternatives? Comparison with an appropriate reference standard can contribute when the procedure and acceptance criteria are sufficiently selective. Retention behavior may also gain specificity when combined with spectral or mass information. Peak height or area alone, however, does not assign a chemical name. Within its pharmaceutical scope, ICH Q6A cautions that retention-time agreement alone generally lacks specificity; adequate discrimination may instead depend on combining methods based on different principles.2
That is why the same chromatogram can support a strong compositional statement and a weak identity statement, or the reverse, depending on the procedure. The correct question is not whether “HPLC identifies” in the abstract. It is whether this HPLC procedure, with its reference comparison, selectivity, detector, and controls, supports the identity conclusion being made for this sample.
Chromatographic Percentages Inherit the Method
A reported area percentage begins with integrated peak responses. Its meaning depends on what the method resolved, what the detector responded to, which peaks met the processing and reporting rules, and how the denominator was defined. Wavelength matters in UV detection because compounds can have different absorptivities. Published HPLC-UV work illustrates why differences in relative UV response factors must be evaluated when peak areas are used to estimate impurity weight percentages.4
Separation is equally consequential. Co-eluting species may appear as one peak, and a species that is unresolved, poorly detected, outside the acquisition window, lost during sample preparation, or below a reporting threshold will not be fully represented by area normalization. Changing the stationary phase, mobile phase, pH, or gradient can reveal selectivity that the first method did not provide. A two-dimensional LC-MS study of pharmaceutical peptides, for example, used complementary chromatographic conditions to examine isomeric impurities that shared mass-to-charge values and could overlap the main component in the first separation.5
System suitability criteria can show that the chromatographic system performed as required for the defined procedure; they do not make it answer a broader question. Consistent retention, acceptable resolution, and reproducible integration strengthen a result within the procedure’s intended use.1,3
These limits do not make chromatographic percentages uninformative. They make the wording important. A relative area result can be a rigorous measure of relative detected response under validated conditions. Without appropriate calibration, response factor treatment, recovery, and selectivity, however, it is not automatically an absolute mass fraction, complete impurity accounting, molecular identity, structural confirmation, safety finding, or suitability decision.
Mass Agreement Narrows Identity Without Finishing It
Mass spectrometry adds a different class of evidence. The instrument records signals from gas-phase ions as a function of mass to charge ratio (m/z), rather than measuring a neutral molecule’s mass directly.6 Interpretation therefore includes the ion species: charge state, protonation or deprotonation, adduct assignment, and, where useful, the isotope pattern. Ionization mode, source conditions, mass analyzer, calibration, resolution, acquisition range, and processing all shape what is observed.6,7
When assigned ions agree with values expected for the proposed molecule, the result narrows the identity assessment. Coherent charge states, plausible adducts, accurate mass, and an expected isotopic envelope may strengthen that inference when relevant and adequately resolved. The conclusion is still conditional: the observed ions are consistent with the expected species under the stated method. Ion abundance is not a chromatographic purity percentage, and electrospray response may change with the analyte, co-eluting matrix, and source conditions.7,10
Fragmentation can add further discrimination. In tandem MS, a selected precursor is fragmented and the product-ion pattern can provide sequence or substructural information. Coverage, mass accuracy, precursor isolation, fragmentation behavior, and the interpretation workflow determine how much confidence that pattern warrants.8 Even then, the question must be specific. Isomers can share nominal and exact mass, positional alternatives may yield incomplete discrimination, and stereochemistry generally requires evidence capable of resolving stereochemical differences.5,9
For those reasons, agreement with an expected mass may support identity without establishing complete sequence or structure. A single MS result also does not, by itself, establish chromatographic purity, safety, biological activity, or suitability. Those are different measurements or judgments, not defects that can be repaired by stronger wording.
Orthogonal Evidence Reduces Different Uncertainties
Orthogonal procedures use different measurement principles and can constrain different uncertainties. Complementary evidence may also add value even when it is not strictly independent. Chromatography can describe separation and the relative detector-response profile under selected conditions. MS can add mass-related evidence for the species associated with a signal. A second separation, spectroscopy, amino acid analysis, nuclear magnetic resonance, ion mobility, or a stereospecific technique may address an ambiguity left by both, depending on the molecule and the claim.
There is no universal instrument panel that converts uncertainty into proof. The analytical question should determine the method, and plausible alternatives should determine the needed selectivity. ICH Q2(R2) describes comparison with a well characterized procedure using a different measurement principle as one way to demonstrate selectivity, while recognizing that a combination is warranted when one procedure does not discriminate sufficiently.1 The value lies in reducing a defined uncertainty.
Seven Questions That Keep Claims Inside the Evidence
A reader does not need to reproduce the experiment to test whether a report’s conclusion is proportionate. Seven questions expose most interpretive leaps:
1. What characteristic was measured? Separate identity, relative detector-response profile, assay, structural characterization, and other attributes before considering the result.
2. Which method was used? Record the separation mode, detector or mass analyzer, and the procedure’s stated purpose rather than relying on an instrument acronym.
3. What sample or lot was actually tested? Confirm that the identifiers on the report connect the result to the material under discussion; evidence from another lot may inform process consistency, but it does not directly establish the result for this lot.
4. What result was directly observed? Distinguish peak areas, retention behavior, m/z values, isotope envelopes, fragment ions, and calculated outputs from the conclusion placed beside them.
5. What comparison or reference was used? Look for an appropriate standard, expected-mass calculation, spectral library, blank, control, or orthogonal procedure, and ask what role it played.
6. What limitations apply? Consider co-elution, detector response, reporting thresholds, sample preparation, ionization, unresolved isomers, calibration, and method suitability as relevant to the claim.
7. Does the conclusion extend beyond the measurement? If the report moves from relative response to mass fraction, from retention to identity, or from mass agreement to complete structure, identify the added assumptions.
An ungated educational example on peptide identity testing versus purity testing applies these questions in one specific context. It is background for report reading, not scientific evidence for the analytical claims in this article.
Conclusion
“Purity” and “identity” should not be used interchangeably. Analytical confidence improves when every conclusion remains attached to the question the procedure was designed to answer and to the sample actually measured. Orthogonal methods can strengthen an assessment, but they do not create absolute proof. Disciplined interpretation is more modest than a one-number verdict and more scientifically useful.
References
1. International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. ICH Harmonised Guideline Q2(R2): Validation of Analytical Procedures. Final version. Adopted November 1, 2023; corrected April 4, 2025. Accessed August 11, 2026. https://database.ich.org/sites/default/files/ICH_Q2%28R2%29_Guideline_2023_1130_ErrorCorrection_2025.pdf
2. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH Harmonised Tripartite Guideline Q6A: Specifications: Test Procedures and Acceptance Criteria for New Drug Substances and New Drug Products: Chemical Substances. Step 4 version. October 6, 1999. Accessed August 11, 2026. https://database.ich.org/sites/default/files/Q6A%20Guideline.pdf
3. United States Pharmacopeia. General Chapter <621> Chromatography. USP-NF. Published 2025. Accessed August 11, 2026. doi:10.31003/USPNF_M99380_10_01
4. Nussbaum MA, Baertschi SW, Jansen PJ. Determination of relative UV response factors for HPLC by use of a chemiluminescent nitrogen-specific detector. J Pharm Biomed Anal. 2002;27(6):983-993. doi:10.1016/S0731-7085(01)00545-3
5. Petersson P, Buckenmaier S, Euerby MR, Stoll DR. A strategy for assessing peak purity of pharmaceutical peptides in reversed-phase chromatography methods using two-dimensional liquid chromatography coupled to mass spectrometry. Part I: Selection of columns and mobile phases. J Chromatogr A. 2023;1693:463874. doi:10.1016/j.chroma.2023.463874
6. Murray KK, Boyd RK, Eberlin MN, Langley GJ, Li L, Naito Y. Definitions of terms relating to mass spectrometry (IUPAC Recommendations 2013). Pure Appl Chem. 2013;85(7):1515-1609. doi:10.1351/PAC-REC-06-04-06
7. Prabhu GRD, Williams ER, Wilm M, Urban PL. Mass spectrometry using electrospray ionization. Nat Rev Methods Primers. 2023;3:23. doi:10.1038/s43586-023-00203-4
8. Steen H, Mann M. The abc’s (and xyz’s) of peptide sequencing. Nat Rev Mol Cell Biol. 2004;5(9):699-711. doi:10.1038/nrm1468
9. Jansson ET. Strategies for analysis of isomeric peptides. J Sep Sci. 2018;41(1):385-397. doi:10.1002/jssc.201700852
10. Taylor PJ. Matrix effects: the Achilles heel of quantitative high-performance liquid chromatography-electrospray-tandem mass spectrometry. Clin Biochem. 2005;38(4):328-334. doi:10.1016/j.clinbiochem.2004.11.007
